439 related articles for article (PubMed ID: 26939747)
21. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
[TBL] [Abstract][Full Text] [Related]
22. Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment.
Matsumoto H; Ohashi H; Fujita Y; Yoshida S; Yokose K; Temmoku J; Matsuoka N; Shinden Y; Kusano K; Sonobe T; Nakamoto Y; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Feb; 256(2):169-174. PubMed ID: 35236806
[TBL] [Abstract][Full Text] [Related]
23. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.
Demirkaya E; Erer B; Ozen S; Ben-Chetrit E
Rheumatol Int; 2016 Mar; 36(3):325-31. PubMed ID: 26687683
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review.
Karadeniz H; Güler AA; Atas N; Satış H; Salman RB; Babaoglu H; Tufan A
Rheumatol Int; 2020 Jan; 40(1):169-173. PubMed ID: 31813060
[TBL] [Abstract][Full Text] [Related]
26. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
27. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.
Yildirim T; Yilmaz R; Uzerk Kibar M; Erdem Y
J Nephrol; 2018 Jun; 31(3):453-455. PubMed ID: 29446001
[TBL] [Abstract][Full Text] [Related]
28. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
Calligaris L; Marchetti F; Tommasini A; Ventura A
Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
[TBL] [Abstract][Full Text] [Related]
30. Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
Yazılıtaş F; Aydoğ Ö; Özlü SG; Çakıcı EK; Güngör T; Eroğlu FK; Gür G; Bülbül M
Rheumatol Int; 2018 May; 38(5):879-885. PubMed ID: 29450637
[TBL] [Abstract][Full Text] [Related]
31. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments.
Ozen S; Kone-Paut I; Gül A
Semin Arthritis Rheum; 2017 Aug; 47(1):115-120. PubMed ID: 28413100
[TBL] [Abstract][Full Text] [Related]
32. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
Karabulut Y; Gezer HH; Duruöz MT
Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
[TBL] [Abstract][Full Text] [Related]
33. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
34. Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?
Erden A; Batu ED; Sarı A; Sönmez HE; Armagan B; Demir S; Fırat E; Bilginer Y; Bilgen SA; Karadağ Ö; Kalyoncu U; Kiraz S; Ertenli I; Özen S; Akdogan A
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):97-102. PubMed ID: 30418112
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
[TBL] [Abstract][Full Text] [Related]
36. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial.
Ben-Zvi I; Livneh A
Isr Med Assoc J; 2014 May; 16(5):271-3. PubMed ID: 24979828
[TBL] [Abstract][Full Text] [Related]
37. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
Laskari K; Boura P; Dalekos GN; Garyfallos A; Karokis D; Pikazis D; Settas L; Skarantavos G; Tsitsami E; Sfikakis PP
J Rheumatol; 2017 Jan; 44(1):102-109. PubMed ID: 28042127
[TBL] [Abstract][Full Text] [Related]
38. Cardiac disease in familial Mediterranean fever.
Erken E; Erken E
Rheumatol Int; 2018 Jan; 38(1):51-58. PubMed ID: 29051974
[TBL] [Abstract][Full Text] [Related]
39. The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients.
Colak S; Tekgoz E; Cinar M; Yilmaz S
Mod Rheumatol; 2021 Jan; 31(1):223-225. PubMed ID: 31903820
[TBL] [Abstract][Full Text] [Related]
40. [Familial Mediterranean fever: not to be missed].
Frenkel J; Bemelman FJ; Potter van Loon BJ; Simon A
Ned Tijdschr Geneeskd; 2013; 157(18):A5784. PubMed ID: 23635502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
